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ABSTRACT 
 
Background:  Treatment failure is increasingly common in Staphylococcus aureus bacteremia 
(SAB).  Vancomycin tolerance may be playing a role in clinical outcomes in SAB that has yet to 
be fully explored.   
Methods:  This was a single-center retrospective cohort study of 166 patients (September 2012 – 
January 2014) evaluating the relationship between vancomycin tolerance and clinical failure in 
SAB.  Vancomycin minimum inhibitory concentration (MIC) was determined by broth 
microdilution and Etest.  Vancomycin tolerance was defined as a vancomycin minimum 
bactericidal concentration (MBC)/MIC ≥ 32.  Univariable and multivariable analyses were 
conducted to determine the relationship between vancomycin tolerance and clinical failure after 
adjusting for other factors. 
Results:  Of the 166 patients evaluated, 26.5% had vancomycin tolerant clinical isolates.  
Tolerance to vancomycin was more common in methicillin-susceptible S. aureus bacteremia 
(MSSA-B) than methicillin-resistant S. aureus bacteremia (MRSA-B; n=29/101 [28.7%] vs. 
n=15/65 [23.1%]), although not significantly (P=0.422).  Clinical failure was frequently 
observed (50% overall).  Elevated vancomycin MIC by Etest (≥ 1.5 μg/mL) was not associated 
with clinical failure (P=0.50).  Vancomycin tolerance was significantly associated with SAB 
clinical failure in univariable analysis (P=0.014). This relationship persisted even when adjusting 
for other factors in multivariable analysis (adjusted odds ratio [AOR], 2.70;  95% confidence 
interval [CI], 1.27-5.70; P=0.010). 
Conclusions:  Vancomycin tolerance is a clinically significant predictor of clinical failure in 
SAB independent of methicillin susceptibility and antibiotic choice.  Future research is needed to 
determine optimal treatment of vancomycin tolerant SAB. 
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INTRODUCTION 
 
Staphylococcus aureus is a well-known opportunistic pathogen and the most frequently 
encountered bacterial species in clinical practice.
1
  Staphylococcus aureus is implicated in a 
variety of invasive disease, including bacteremia.
2
  Staphylococcus aureus bacteremia (SAB) is a 
life-threatening condition, with an overall mortality of 20%.
3
  The incidence of S. aureus 
bacteremia is approximately 20 in 100,000 persons and increases with age.
4,5
  While most cases 
of SAB are caused by methicillin-susceptible strains (MSSA), the incidence of methicillin-
resistant S. aureus (MRSA) is increasing in recent years and may be associated with increased 
mortality.
3
   
 The glycopeptide antibiotic vancomycin has been the mainstay of MRSA treatment since 
its introduction in the late 1950s.
6,7
  Although high-level resistance to vancomycin in MRSA is 
limited to a few cases worldwide, treatment failure is common – even when the isolate tests 
susceptible (vancomycin minimum inhibitory concentration (MIC) ≤ 2 μg/mL).
8-11
  Moreover, 
the increasing prevalence of elevated vancomycin MIC (“MIC creep”) has presented new 
treatment challenges.
11-13
  While the results from studies investigating the clinical implications of 
elevated vancomycin MIC show conflicting evidence, a recent meta-analysis found that 
vancomycin MIC ≥ 1.5 μg/mL by Etest is associated with treatment failure in MRSA bacteremia 
(MRSA-B) and vancomycin MIC 2 μg/mL is associated with increased mortality, regardless of 
methodology..
14
  However, elevated vancomycin MIC is not unique to MRSA-B and has also 
been independently associated with β-lactam failure in MSSA bacteremia (MSSA-B)..
15,16
  Thus, 
although elevated vancomycin MIC is associated with poorer outcomes in SAB, this 
phenomenon may simply be a marker for some other pathogen-specific factor(s) that have yet to 
be determined. 
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 Previous studies have demonstrated superiority of antimicrobial regimens featuring a 
bactericidal agent in the treatment of SAB.
10,17,18
  Therefore, it is intuitive that bactericidal 
activity (≥ 99.9% killing in vitro after 24 hours) may be a more clinically relevant predictor of 
therapeutic effectiveness than measures of inhibitory activity.  As expected, reduced bactericidal 
activity of vancomycin is associated with poor outcomes in MRSA-B, including longer duration 
of bacteremia and increased vancomycin treatment failure.
10,19
  Although vancomycin MIC and 
minimum bactericidal concentrations (MBC) are highly correlated, there are instances in which 
there is a large dissociation between these values.
20
  Vancomycin tolerance is defined as a 
MBC/MIC ratio of ≥ 32.
21
  Vancomycin tolerance is found in 20% of MRSA isolates overall, 
although the prevalence is as high as 43% in some institutions.
22
  Like elevated vancomycin 
MIC, vancomycin tolerance is also observed in MSSA and may be even more prevalent in these 
infections.
23
   
We hypothesize that vancomycin tolerance may be associated with clinical failure in 
SAB.  Although the relationship between vancomycin bactericidal activity and clinical outcomes 
has been explored, the clinical implications of highly dissociated inhibitory and bactericidal 
activities (i.e., tolerance) remain unclear.
24
  Therefore, the objective of this study was to evaluate 
the relationship between vancomycin tolerance and clinical outcomes in the treatment of SAB.   
METHODS  
Study Population 
 
This was a retrospective cohort study of hospitalized patients at the University of Kansas 
Hospital, a tertiary care academic medical center.  All adult patients with a positive blood culture 
for S. aureus from September 2012 through January 2014 were eligible for inclusion.  Patients 
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were excluded if they received antimicrobial therapy targeted against SAB for < 48 hours or if 
they exhibited polymicrobial bacteremia at onset.  Clinical data was collected by retrospective 
review of the electronic medical record.  Variables that were collected included basic patient 
demographics (age, gender), setting of bacteremia onset, comorbidities, Charlson comorbidity 
index, associated focus of SAB, antimicrobial treatment data, laboratory values, vital signs, and 
microbiological data.  Bacteremia was considered hospital-acquired if all elements of infection 
were first present on or after the third hospital day.   The associated focus of SAB was 
determined as documented by a treating physician and stratified according to risk for mortality as 
described by Soriano et al.
25
  Immunosuppression was defined as neutropenia, leukopenia, 
chronic steroid (≥ 20 mg prednisone) or antineoplastic use, or as diagnosed by a treating 
physician.  This study was approved by the University of Kansas Medical Center institutional 
review board. 
Outcome Measures 
 
The primary outcome was clinical failure, defined as a composite of:  i) 30-day all-cause 
mortality; ii) non-resolving signs and symptoms of bacteremia (body temperature ≥ 38
o
C, white 
blood cell count ≥ 12,000/μL, persistent positive blood cultures) for ≥ 5 days while on 
antimicrobial therapy;  iii) perceived treatment failure, leading to either change of antimicrobial 
or addition of a second agent targeted against S. aureus;  iv) recurrent bacteremia within 60 days 
of the index SAB episode;  or v) relapsing bacteremia, defined as a positive blood culture for S. 
aureus following a previous negative culture during the same SAB episode.   
Secondary outcomes were 30-day all-cause mortality, duration of bacteremia, and 
hospital length of stay (LOS).  Hospital LOS was defined as the date of first positive S. aureus 
blood culture until date of discharge.  Duration of bacteremia was defined as the time from the 
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first positive S. aureus blood culture until the first negative blood culture or complete 
resolution of signs and symptoms of SAB.   
Microbiological Analysis 
 
Clinical S. aureus blood isolates were stored at -70
o
C prior to microbiological testing.   
Strains were subcultured three times post-freezing to ensure uniform growth and adequate 
metabolic activity prior to evaluation.  Vancomycin MIC was determined by broth microdilution 
according to Clinical and Laboratory Standards Institute (CLSI) guidelines.
26
  Vancomycin MIC 
was also determined by Etest according to manufacturer recommendations (bioMérieux, Marcy 
l’Etoile, France).  Vancomycin MIC ≥ 2 μg/mL by broth microdilution or ≥ 1.5 μg/mL by Etest 
were classified as elevated.  Methicillin resistance was confirmed by the presence of penicillin-
binding protein 2a (PBP-2a) by latex agglutination.  For patients with multiple clinical S. aureus 
blood isolates during the study period, only the first isolate was analyzed. 
The MBC was determined according to CLSI recommendations using the microdilution 
method.
21
  Briefly, a 100 μL aliquot of each well with no visible growth after 24 hours of 
incubation at 35
o
C was subcultured on tryptic soy agar, allowed to visibly dry at room 
temperature, and cross-streaked using a sterile cotton-tipped swab to account for antibiotic 
carryover.  Vancomycin MBC was defined as the lowest concentration of drug with ≥ 99.9% 
killing at 24 hours.   Clinical isolates with a vancomycin MBC/MIC ≥ 32 by broth microdilution 
were determined to be vancomycin tolerant. 
Statistical Analysis 
 
Categorical variables were compared by χ
2
 or two-tailed Fisher’s exact test and 
continuous variables were compared by Student’s t-test or Mann-Whitney U test with a two-
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sided P-value < 0.05 considered statistically significant.  Multivariable logistic regression was 
performed to determine variables independently associated with clinical failure.  All calculations 
were performed using SPSS statistical software (version 20.0; IBM Corp.: Armonk, NY). 
RESULTS 
 
A total of 166 patients met study criteria and were included in the final analysis.  
Vancomycin tolerance was observed in 44 (26.5%) of the 166 S. aureus clinical isolates tested.  
Although tolerance to vancomycin appeared to be more common in MSSA-B than MRSA-B 
(28.7%, n=29/101 vs. 23.1%, n=15/65), this difference was not statistically significant 
(P=0.422).  Baseline characteristics of patients with a vancomycin tolerant clinical isolate were 
compared to those without a vancomycin tolerant isolate, as displayed in Table 1.  There were no 
statistically significant differences observed across baseline characteristics.   
The distribution of vancomycin MIC by broth microdilution and corresponding 
MBC/MIC ratios are displayed in Table 2.  As shown, 51.8% of the 166 clinical isolates 
analyzed had equal vancomycin MIC and MBC values.  Elevated MIC by broth microdilution 
was only observed in 2 of the 166 isolates (1.2%) in this cohort.  However, elevated MIC by 
Etest was observed in 100 of 166 clinical isolates (60.2%).  The majority of isolates (56.6%, 
n=94/166)  had a vancomycin MIC by Etest of 1.5 μg/mL.  Vancomycin MIC of 1 μg/mL by 
Etest was also commonly observed (35.5%, n=59/166).  A vancomycin MIC ≥ 2 μg/mL by Etest 
was rarely encountered in this cohort (3.6%; n=6/166).  Elevated vancomycin MIC by Etest was 
not associated with vancomycin tolerance (P=0.588, Table 1). 
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Table 1.   Patient characteristics in Staphylococcus aureus bacteremia according to 
vancomycin tolerance 
 
Characteristic 
Vancomycin 
Tolerant (n=44) 
Non-Vancomycin 
Tolerant (n=122) 
 
P value 
Age (years), mean ± SD 58.1 ± 16.5 59.0 ± 14.9 0.725 
      Age > 65 years, n (%) 15 (34.1) 44 (36.1) 0.815 
      Age > 85 years, n (%) 3 (6.8) 5 (4.1) 0.438
a 
Female gender, n (%) 19 (43.2) 42 (34.4) 0.302 
Methicillin resistance, n (%) 15 (34.1) 50 (41.0) 0.422 
Hospital-acquired, n (%) 15 (34.1) 33 (27.0) 0.377 
Intensive care unit, n (%) 12 (27.3) 39 (32.0) 0.563 
Sepsis, n (%) 28 (63.6) 76 (62.3) 0.875 
Septic shock, n (%) 7 (15.9) 20 (16.4) 0.941 
Immunosuppression, n (%) 13 (29.5) 40 (32.8) 0.693 
High-risk focus, n (%) 12 (27.3) 34 (27.9) 0.940 
      S. aureus pneumonia, n (%) 8 (18.2) 23 (18.9) 0.922 
      S. aureus endocarditis, n (%) 6 (13.6) 12 (9.8) 0.487 
Medium-risk focus, n (%) 24 (54.5) 64 (52.5) 0.812 
      S. aureus osteomyelitis, n (%) 5 (11.4) 10 (8.2) 0.546
a 
Low-risk focus, n (%) 8 (18.2) 23 (18.9) 0.922 
Central line-associated, n (%) 10 (22.7) 25 (20.5) 0.755 
S. aureus bacteruria, n (%) 4 (9.1) 13 (10.7) 1.000
a 
Diabetes mellitus, n (%) 20 (45.5) 52 (42.6) 0.745 
Hemodialysis, n (%) 7 (15.9) 27 (22.1) 0.381 
Charlson com. index, median (IQR) 6 (4-8) 6 (4-9) 0.477
b 
Vancomycin MIC ≥ 1.5 μg/mL
c
, n (%) 25 (56.8) 75 (61.5) 0.588 
    
SD, standard deviation;  IQR, interquartile range;  APACHE II, Acute Physiology and Chronic Health Evaluation II;  MIC, minimum inhibitory 
concentration 
a
 Calculated by Fisher’s exact test; all other categorical variables compared by χ2 test 
b
 Calculated by Mann-Whitney U test; all other continuous variables compared by Student’s t-test 
c
 Determined by Etest 
Table 2.  Vancomycin minimum inhibitory concentrations and minimum bactericidal 
concentration/minimum inhibitory concentration ratios by broth microdilution 
  Vancomycin MBC/MIC 
Vancomycin 
MIC (μg/mL) 
No. isolates (%) 
(N=166) 
1 2 4 8 16 ≥32 
0.25 2 (1.2) --- 1 --- --- --- 1 
0.5 57 (34.3) 19 17 1 2 --- 18 
1 105 (63.3) 65 7 2 4 2 25 
2 2 (1.2) 2 --- --- --- --- --- 
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Clinical failure was common, occurring in 50.0% of cases overall.  Univariable 
comparisons according to antimicrobial clinical success or failure are displayed in Table 3.  As 
shown, clinical failure was more frequent among those with a vancomycin tolerant isolate 
compared to those without a vancomycin tolerant isolate (65.9% vs. 44.3%) and this difference 
was statistically significant (P=0.014).  Other variables that were significantly associated with 
clinical failure on univariable analysis (P < 0.05) were hospital-acquired infection (odds ratio 
[OR], 2.04; 95% confidence interval [CI], 1.03-4.07; P=0.042), intensive care unit (ICU) 
admission (OR, 2.38; 95% CI, 1.20-4.72, P=0.012), sepsis (OR, 2.31; 95% CI, 1.21-4.41; 
P=0.010), septic shock (OR, 4.35;  95% CI, 1.65-11.43;  P=0.002), high-risk focus of infection 
(OR, 2.09;  95% CI, 1.04-4.20, P=0.037), and S. aureus pneumonia (OR, 2.57;  95% CI, 1.08-
5.65, P=0.028).  Elevated vancomycin MIC by Etest was not significantly associated with 
clinical failure (P=0.526). 
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SD, standard deviation;  IQR, interquartile range;  APACHE II, Acute Physiology and Chronic Health Evaluation II;  MIC, minimum inhibitory 
concentration 
a
 Calculated by Fisher’s exact test; all other categorical variables compared by χ2 test 
b
 Calculated by Mann-Whitney U test; all other continuous variables compared by Student’s t-test 
c
 Determined by Etest 
Multivariable logistic regression was conducted to evaluate the relationship between 
vancomycin tolerance and clinical failure after adjusting for potential confounders.  All variables 
that were associated with vancomycin tolerance or clinical failure in univariable analysis (P < 
0.20) were eligible for inclusion in the explanatory model.  As displayed in Table 4, the 
association between vancomycin tolerance and clinical failure persisted when adjusting for other 
factors in multivariable logistic regression (adjusted odds ratio [AOR], 2.67; 95% CI, 1.26-5.64;  
 
Table 3.   Patient characteristics in Staphylococcus aureus bacteremia according to 
clinical failure 
 
Characteristic 
Clinical Failure 
(n=83) 
Clinical Success 
(n=83) 
 
P value 
Age (years), mean ± SD 59.4 ± 16.6 58.1 ± 13.8 0.588 
      Age > 65 years, n (%) 31 (37.3) 28 (33.7) 0.627 
      Age > 85 years, n (%) 7 (8.4) 1 (1.2) 0.064
a 
Vancomycin tolerance, n (%) 29 (34.9) 15 (18.1) 0.014 
Female gender, n (%) 33 (39.8) 28 (33.7) 0.421 
Methicillin resistance, n (%) 33 (39.8) 32 (38.6) 0.874 
Hospital-acquired, n (%) 30 (36.1) 18 (21.7) 0.040 
Intensive care unit, n (%) 33 (39.8) 18 (21.7) 0.012 
Sepsis, n (%) 60 (72.3) 44 (53.0) 0.010 
Septic shock, n (%) 21 (25.3) 6 (7.2) 0.002 
Immunosuppression, n (%) 22 (26.5) 31 (37.3) 0.134 
High-risk focus, n (%) 30 (36.1) 19 (22.9) 0.061 
      S. aureus pneumonia, n (%) 21 (25.3) 10 (12.0) 0.028 
      S. aureus endocarditis, n (%) 9 (10.8) 9 (10.8) 1.000 
Medium-risk focus, n (%) 38 (45.8) 47 (56.6) 0.162 
      S. aureus osteomyelitis, n (%) 8 (9.6) 7 (8.4) 0.787 
Low-risk focus, n (%) 14 (16.9) 17 (20.5) 0.550 
Central line-associated, n (%) 17 (20.5) 18 (21.7) 0.849 
S. aureus bacteruria, n (%) 11 (13.3) 6 (7.2) 0.201 
Diabetes mellitus, n (%) 35 (42.2) 37 (44.6) 0.754 
Hemodialysis, n (%) 16 (19.3) 18 (21.7) 0.701 
Charlson com. index, median (IQR) 6 (4-8) 6 (4-9) 0.595
b 
Vancomycin MIC ≥ 1.5 μg/mL
c 
48 (57.8) 52 (62.7) 0.526 
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P=0.010).  Septic shock was also independently associated with clinical failure (AOR, 4.34;  
95% CI, 1.60-11.74; P=0.004) in this model.   Although ICU admission and sepsis were 
associated with clinical failure in univariable analysis, these factors were not included in the final 
model due to shared variance with septic shock, which is an established predictor of poor 
outcomes in SAB.
3
   
Table 4.   Multivariable logistic regression  model of variables associated with clinical 
failure in Staphylococcus aureus bacteremia 
 
Variable (N=166) 
Adjusted Odds Ratio 
(95% CI) 
 
P value 
Age (years) 1.00 (0.98-1.03) 0.678 
Septic shock 4.34 (1.60-11.74) 0.004 
S. aureus pneumonia 2.23 (0.95-5.47) 0.065 
Vancomycin tolerance 2.67 (1.26-5.64) 0.010 
   
CI,  confidence interval  
 
All of the patients in this study received appropriate empiric treatment within 24 hours of 
positive S. aureus blood culture.  Following empiric vancomycin therapy in cases of MSSA-B 
(n=101), 46 patients (45.5%) were treated primarily with a penicillin (nafcillin or piperacillin-
tazobactam), 27 patients (26.7%) were treated with a cephalosporin, and 26 patients  (25.7%) 
were treated with vancomycin.  The vast majority (90.8%) of MRSA-B cases were treated with 
vancomycin.  The other 9.2% of cases were treated with daptomycin.  Treatment with 
vancomycin was not associated with clinical failure in SAB overall (P=0.277).  When restricting 
our analysis to patients with MSSA-B, vancomycin tolerance was associated with clinical failure 
of not only vancomycin therapy (100%, n=4/4 vs. 42.9%, n=9/21), but β-lactam therapy as well 
(64.0%, n=16/25  vs. 38.3%, n=18/47; P=0.038).  
A summary of all clinical outcomes measured is included in Table 5.  Overall, 30-day all-
cause mortality was observed in 15.1% of cases.  Mortality was lower in the vancomycin tolerant 
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group (11.4% vs. 16.4%), although this difference was not statistically significant (P=0.424).  
Overall median hospital LOS was 9 days (interquartile range [IQR], 5-16 days).  As shown, the 
observed difference in clinical failure between groups was driven primarily by non-resolving 
signs and symptoms of SAB (36.3% vs. 15.6%; P=0.004).  Median LOS was longer in the 
vancomycin tolerant group (10.0 days vs. 9.0 days), although this relationship was not 
statistically significant (P=0.342).  The median duration of SAB for this cohort was 66.0 hours 
(IQR, 38.5-97.0 hours).  There was not a significant association between vancomycin tolerance 
and median duration of SAB (P=0.725).   
Table 5.   Comparison of clinical outcomes by vancomycin tolerance in Staphylococcus 
aureus bacteremia 
 
Outcome 
Vancomycin 
Tolerant (n=44) 
Non-Vancomycin 
Tolerant (n=122) 
P 
value 
Clinical failure, n (%) 
a
 29 (65.9) 54 (44.3) 0.014 
     30-day all cause mortality 5 (11.4) 20 (16.4) 0.424 
     Non-resolving signs/symptoms ≥ 5 d 16 (36.3) 19 (15.6) 0.004 
     Persistent bacteremia 7 (15.9) 20 (16.4) 0.941 
     Relapsing bacteremia 2 (4.5) 1 (0.8) 0.172
b 
     60-day recurrence 0 (0.0) 1 (0.8) 1.000
b 
Hospital LOS (days), median (IQR) 10.0 (6.0-14.0) 9.0 (5.0-18.0) 0.342 
Bacteremia duration (hrs), median (IQR) 64.0 (41.0-90.0) 66.0 (38.0-105.25) 0.725 
    
LOS, length of stay;  IQR, interquartile range 
a
  Composite endpoints may not add up if multiple outcomes contributed to clinical failure 
b
  Calculated by Fisher’s exact test 
DISCUSSION 
 
The purpose of this study was to evaluate the relationship between vancomycin tolerance 
and clinical outcomes in SAB.  After adjusting for host factors, we found an independent 
association between vancomycin tolerance and clinical failure in SAB, irrespective of methicillin 
susceptibility and antibiotic choice.  While previous researchers have detailed the importance of 
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vancomycin bactericidal activity in this setting, data supporting the clinical relevance of 
vancomycin tolerance, particularly the ≥ 32 MBC/MIC breakpoint, are limited to a single case 
series.
17
  Antibiotic tolerance is well-documented in the literature and data from previous studies 
in other settings suggest that tolerance is likely not just an in vitro phenomenon, but may have 
clinical implications.
17,18
  Notably, Rahal et al. noted an association between β-lactam tolerance 
and increased duration of clinical symptoms of infection, despite patients not requiring additional 
antimicrobial agents to eventually achieve cure.
18
  This is similar to our findings in that 
microbiological cure was achieved relatively quickly in both the vancomycin tolerant and non-
tolerant group, but clinical signs and symptoms persisted longer when tolerance was observed in 
vitro, ultimately leading to a higher rate of clinical failure. 
The “paradoxical effect” is an in vitro phenomenon commonly encountered in 
bactericidal activity testing for cell wall-active agents.
21
  Observation of this phenomenon is 
credited to Eagle and colleagues, in which they observed that S. aureus was paradoxically killed 
more slowly at higher concentrations of benzylpenicillin than at concentrations slightly above the 
MIC.
27
  A similar effect has been observed with vancomycin in MRSA in vitro and represents a 
potential mechanism of vancomycin tolerance.
28
  It is believed that at lower inhibitory 
concentrations, vancomycin acts simply by binding to C-terminal D-alanyl-D-alanine residues, 
blocking the transglycosylation reaction required for cell wall synthesis.
28
  However, at 
concentrations of 12 μg/mL or greater, a transient vancomycin intermediate S. aureus (VISA)-
like phenomenon occurs in which vancomycin binding consequently blocks access of murein 
hydrolases to substrates, leading to inhibition of the cell wall autolytic system and vancomycin 
tolerance.
28
  If tolerance can be induced at vancomycin concentrations that would be observed in 
vivo, it is plausible that this may have clinical implications in the treatment of staphylococcal 
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infections, including SAB.
29,30
  The observed increase in clinical failure associated with the 
vancomycin tolerant phenotype described in the present study support this hypothesis.   
It is important to note that although vancomycin tolerance was associated with increased 
clinical failure in this cohort, a difference in 30-day all-cause mortality was not observed.  
Rather, it appears that mortality may even be lower when vancomycin tolerance is observed in 
vitro.  The heteroresistant VISA (hVISA) phenotype has been independently associated with 
increased treatment failure and persistent bacteremia, yet decreased mortality in SAB.
3,31
  This 
phenomenon appears to be due to alterations in the accessory gene regulator (agr) controlling for 
virulence in S. aureus.
32
  In a study of clinical MRSA blood isolates, the agr group II genotype 
was associated with reduced vancomycin bactericidal activity (MBC/MIC ≥ 8 μg/mL) in time-
kill assays.
24
  Although we did not perform agr genotyping in this study, the lack of an observed 
mortality increase despite high rates of clinical failure suggest a possible interplay between agr 
genotype, virulence, and vancomycin tolerance that needs to be further explored.   
Previous researchers have hypothesized that conflicting results from studies examining 
the relationship between elevated vancomycin MIC and clinical outcomes in SAB may be 
partially explained by unmeasured phenotypic variation or reduced vancomycin bactericidal 
activity.
20,24
  The observation that vancomycin tolerance, but not elevated vancomycin MIC by 
Etest was significantly associated with clinical failure in SAB is a novel and intriguing finding 
that supports this hypothesis.  This observation may also be attributed to geographic variation in 
vancomycin MIC distributions and tolerance rates.  Importantly, the frequency of vancomycin 
MIC ≥ 2 μg/mL by Etest that we observed was significantly less than other studies in which a 
difference in treatment failure was noted.
14
  Therefore, although the relationship between 
elevated vancomycin MIC and clinical outcomes is well-established in the literature, it is also 
13 
 
possible that vancomycin tolerance may be a more reliable of clinical failure in SAB at some 
institutions.
14,33
  As no association between vancomycin tolerance and elevated MIC was 
observed in this cohort, these phenotypes appear to be caused by distinct mechanisms.  We 
observed vancomycin tolerance in 26.5% of clinical isolates, which is consistent with 
percentages described at some other institutions (range 10% to 43%; mean 20.1%).
22
  Of note, 
we included patients with MSSA-B in our analyses due to the high prevalence of vancomycin 
tolerance in this population.  Additionally, we used an enhanced methodology for MBC testing.  
Specifically, the cross-streaking technique described by Pelletier and Baker was used to reduce 
false negatives caused by antibiotic carryover, which is most commonly encountered at drug 
concentrations ≥4 x MIC.
21,34
    
The finding that vancomycin tolerance is more prevalent among MSSA isolates is 
consistent with previous research.
23
  This result is not surprising, as the mechanism of 
vancomycin tolerance is believed to result from phenotypic changes in the cell wall autolytic 
mechanism, independent of the mecA gene.
28,35
  Holmes et al. recently described an association 
between elevated vancomycin MIC and increased 30-day mortality in patients with SAB;  
however, elevated vancomycin MIC was also predictive of mortality in those who received 
antistaphylococcal penicillin (flucloxacillin) therapy for MSSA-B.
15
  As vancomycin and β-
lactams both act at similar sites in the bacterial cell wall, it is not overly surprising that 
pathogenic changes resulting in elevated vancomycin MIC may also lead to decreased efficacy 
of other cell wall-active agents.  Our finding that vancomycin tolerance was independently 
predictive of clinical failure regardless of methicillin susceptibility and antibiotic choice is 
suggestive of a similar effect with vancomycin tolerance.   
14 
 
This study was limited by its retrospective nature and relatively small sample size.  In 
SAB, the definition of clinical failure is arbitrary and inconsistent across studies.  We chose to 
use an inclusive definition which was a composite of multiple negative outcomes .  The observed 
difference in clinical failure was driven primarily by persisting signs and symptoms of SAB ≥ 5 
days while on antimicrobial therapy;  however, this didn’t translate into significant increases in 
mortality or length of stay in this cohort.  It is not known whether this would hold true if 
adequate power was achieved to test these secondary outcomes.  We believe the inclusion of 
both MSSA-B and MRSA-B cases and the use of an enhanced methodology for MBC testing 
that accounted for in vitro antibiotic carryover were important strengths of this study.  Given the 
high prevalence of elevated vancomycin MIC and vancomycin tolerance in MSSA-B, we believe 
these cases should be included in future investigations of SAB.
15
   
In summary, vancomycin tolerance, but not elevated vancomycin MIC, was significantly 
associated with clinical failure in SAB regardless of methicillin susceptibility or antibiotic 
choice.  This association persisted even when adjusting for host factors in multivariable analysis.  
This finding adds to the growing body of evidence demonstrating the importance of bactericidal 
activity in SAB.  Tolerance to vancomycin occurs irrespective of methicillin susceptibility and 
represents a clinically significant  bacterial phenotype that warrants continued investigation.  
Future research is needed to determine optimal treatment of vancomycin tolerant S. aureus 
infections. 
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